J. Costin

发表

Novel oral anticoagulants and reversal agents: Considerations for clinical development.

Jonathan H Seltzer, D. Singer, P. Kowey, 2015, American heart journal.

Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban

M. Mercuri, J. Ansell, S. Bakhru, 2016, Thrombosis and Haemostasis.

The new oral anticoagulants: clinical use and reversal agent development

J. Ansell, S. Bakhru, S. Steiner, 2015 .

Use of PER977 to reverse the anticoagulant effect of edoxaban.

J. Ansell, S. Bakhru, M. Grosso, 2014, The New England journal of medicine.

PER977 REVERSES LOW MOLECULAR WEIGHT HEPARIN IN ADDITION TO IIA AND XA NEW ORAL ANTICOAGULANTS

S. Bakhru, S. Steiner, James C Costin, 2015 .

Abstract 18809: PER977: A Synthetic Small Molecule Which Reverses Over-Dosage and Bleeding by the New Oral Anticoagulants

H. Masumoto, S. Bakhru, M. Grosso, 2013, Circulation.

Abstract 11395: Small Molecule Antidote for Anticoagulants

E. Mathiowitz, S. Bakhru, S. Steiner, 2012 .

Reversal Agents in Development for the New Oral Anticoagulants

J. Ansell, S. Bakhru, S. Steiner, 2014, Postgraduate medicine.

Abstract 19361: Reversal of Anticoagulant-induced Bleeding in External and Internal Bleeding Models by PER977, a Small Molecule Anticoagulant Antidote

M. Mercuri, H. Masumoto, S. Bakhru, 2014 .

Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin.

J. Ansell, S. Bakhru, M. Hoffman, 2016, Thrombosis research.